No association of rs1065852 and rs3892097 polymorphisms gene CYP2D6 with treatment resistant schizophrenia
https://doi.org/10.31363/2313-7053-2019-4-1-128-129
Abstract
According to modern data, about a third of patients suffering from schizophrenia are considered treatment resistant. The metabolism of about 20% of medicines and mainly psychotropic drugs is caused by the isoenzyme CYP2D6. This article presents the data of the CYP2D6 gene study as biomarkers for the treatment resistant schizophrenia. The study included 130 patients, men (65.4%) and women (34.6%) aged 18 to 60 years with schizophrenia. Based on the results, we found no effect of rs1065852 and rs3892097 polymorphisms gene CYP2D6 on treatment resistant schizophrenia.
About the Authors
D. N. Sosin
V.M. Bekhterev national research medical center for psychiatry and neurology
Russian Federation
Russian Federation
M. V. Ivanov
V.M. Bekhterev national research medical center for psychiatry and neurology
Russian Federation
Russian Federation
L. M. Muslimova
V.M. Bekhterev national research medical center for psychiatry and neurology
Russian Federation
Russian Federation
D. V. Ivashchenko
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Review
For citations:
Sosin D.N., Ivanov M.V., Muslimova L.M., Ivashchenko D.V., Sychev D.A. No association of rs1065852 and rs3892097 polymorphisms gene CYP2D6 with treatment resistant schizophrenia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2019;(4-1):128-129. (In Russ.) https://doi.org/10.31363/2313-7053-2019-4-1-128-129
Views:
651
Email this article 